# Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

> **NCT07751133** · PHASE3 · RECRUITING · sponsor: **University College, London** · enrollment: 1500 (estimated)

## Conditions studied

- Prostate Cancer
- mHSPC
- mCRPC

## Interventions

- **DRUG:** Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy

## Key facts

- **NCT ID:** NCT07751133
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2029-08-01
- **Final completion:** 2033-08-01
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751133, "Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07751133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*